Few offer other evidence-based treatments
Likelihood of not taking medication as prescribed due to cost increased for women versus men and for those with disabilities
Ketamine noninferior in terms of response to treatment; ECT linked to decrease in memory recall after treatment
Extended-release injection available in lower doses to be administered in health care settings by health care providers
Risk by age 18 years was driven by disorders within the neurodevelopmental spectrum
Protective effect suggested with female gender for schizophrenia patients with tardive dyskinesia
Patients who received 2 or 3 mg of Rexulti had significant improvements in agitation scores compared with patients taking a placebo
Solriamfetol, armodafinil-modafinil, and pitolisant reduce daytime sleepiness, with solriamfetol likely superior
Extension through Nov. 11, 2023, gives DEA and HHS a chance to consider revisions and public comments regarding proposals offered March 1
Persons receiving medication for opioid use disorder more likely to be older, White and to have public insurance